Raymond James Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Raymond James Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$303K	Sell	82,642 -3,572	-4%	-$11.9K	﹤0.01%	4810
2026 Q1	$265K	Sell	86,214 -28,365	-25%	-$110K	﹤0.01%	4724
2025 Q4	$469K	Sell	114,579 -881	-0.8%	-$4.36K	﹤0.01%	4311
2025 Q3	$563K	Sell	115,460 -2,852	-2%	-$15K	﹤0.01%	4043
2025 Q2	$599K	Sell	118,312 -128,491	-52%	-$631K	﹤0.01%	3900
2025 Q1	$1.31M	Buy	246,803 +156,696	+174%	+$1.14M	﹤0.01%	3295
2024 Q4	$609K	Buy	+90,107	New	+$606K	﹤0.01%	3781

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Raymond James Financial's RXRX Position: Q2 2026 in Review

Raymond James Financial reduced its Recursion Pharmaceuticals (RXRX) stake by 4.1% in Q2 2026, selling an estimated $11.9K and leaving 82,642 shares worth $303K. The position accounts for ﹤0.01% of the portfolio, ranked #4810.

Raymond James Financial first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.31M in Q1 2025. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Raymond James Financial held 82,642 shares of Recursion Pharmaceuticals worth $303K as of Q2 2026.
Raymond James Financial sold 3,572 Recursion Pharmaceuticals shares in Q2 2026, an estimated $11.9K.
Recursion Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4810 holding.
Raymond James Financial first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Recursion Pharmaceuticals position peaked at $1.31M in Q1 2025.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.